Navigation Links
Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team
Date:2/19/2009

NEWARK, Del., Feb. 19 /PRNewswire-FirstCall/ -- Lightwave Logic, Inc. (OTC Bulletin Board: LWLG - News; http://lightwavelogic.com), a technology company focused on the development of electro-optic polymer materials for applications in high speed fiber-optic telecommunications and optical computing, announced today the addition of Anthony J. Cocuzza, PhD to our technology team. Dr. Cocuzza worked for 30 years in medicinal chemistry and brings a highly developed set of synthetic and analytical skills to Lightwave Logic.

A graduate of Princeton, Dr. Cocuzza spent 24 years with DuPont engaged in R&D in corporate R&D and with DuPont's joint venture with Merck. He retired in 2008 from Bristol-Meyers Squib. Cocuzza has contributed to programs in many areas of medicinal and biological chemistry. David Eaton, CTO of Lightwave commented: "We are extremely happy to attract a scientist with Dr. Cocuzza's talents. His capabilities are an excellent match to our needs. We expect he will be able to contribute strongly to our efforts to expand our molecular materials base."

Jim Marcelli, CEO of Lightwave stated, "I'm very excited to have Dr. Cocuzza join the Lightwave family. Tony's experience in organic synthesis will help to streamline our preparation and scale-up of our Perkinamine family of materials."

About Lightwave Logic, Inc.

Lightwave Logic, Inc. is a development stage company, moving toward prototype demonstration and commercialization of its high-activity, high-stability organic polymers for applications in electro-optical device markets. Electro-optical devices convert data from electric signals into optical signals for use in high-speed fiber-optic telecommunications systems and optical computers. Please visit the Company's website, www.lightwavelogic.com, for more information.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.


'/>"/>
SOURCE Lightwave Logic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hologic, Inc. to Host Investor Reception at the RSNA Trade Show
2. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
3. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
4. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
5. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
6. Psychemedics Corporation Announces 2008 Year End Results
7. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
8. Amicus Therapeutics Announces Change to Board of Directors
9. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast
10. Obio Pharmaceutical Announces Product Growth Strategy
11. Pressure BioSciences, Inc. Announces Completion of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... York, NY (PRWEB) , ... October 12, 2017 ... ... Academy of Sciences today announced the three Winners and six Finalists of the ... are given annually by the Blavatnik Family Foundation and administered by the New ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
Breaking Biology Technology:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):